Effective Detection and Monitoring of Glioma Using [18F]FPIA PET Imaging

Vassileva, Vessela; Braga, Marta; Barnes, Clifford A.; Przystal, Justyna M.; Ashek, Ali; Allott, Louis; Bričkutė, Diana; Abrahams, Joel; Suwan, Keittisak; Carcaboso, Ángel M.; Hajitou, Amin; Aboagye, Eric O.

doi:10.3390/biomedicines9070811

Cited by 5 publications

(3 citation statements)

References 36 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET and CT images were co-registered and used to draw 3-dimensional regions of interests (ROIs) over tissues to obtain time–activity curves (TACs). Decay-corrected tissue time versus radioactivity curves (TACs) were generated and normalized to whole-body activity to obtain normalized uptake values (NUVs) [ 41 ].…”

Section: Methodsmentioning

confidence: 99%

Evaluation of [18F]AlF-EMP-105 for Molecular Imaging of C-Met

Teh,

Amgheib,

et al. 2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

C-Met is a receptor tyrosine kinase that is overexpressed in a range of different cancer types, and has been identified as a potential biomarker for cancer imaging and therapy. Previously, a 68Ga-labelled peptide, [68Ga]Ga-EMP-100, has shown promise for imaging c-Met in renal cell carcinoma in humans. Herein, we report the synthesis and preliminary biological evaluation of an [18F]AlF-labelled analogue, [18F]AlF-EMP-105, for c-Met imaging by positron emission tomography. EMP-105 was radiolabelled using the aluminium-[18F]fluoride method with 46 ± 2% RCY and >95% RCP in 35–40 min. In vitro evaluation showed that [18F]AlF-EMP-105 has a high specificity for c-Met-expressing cells. Radioactive metabolite analysis at 5 and 30 min post-injection revealed that [18F]AlF-EMP-105 has good blood stability, but undergoes transformation—transchelation, defluorination or demetallation—in the liver and kidneys. PET imaging in non-tumour-bearing mice showed high radioactive accumulation in the kidneys, bladder and urine, demonstrating that the tracer is cleared predominantly as [18F]fluoride by the renal system. With its high specificity for c-Met expressing cells, [18F]AlF-EMP-105 shows promise as a potential diagnostic tool for imaging cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of [18F]AlF-EMP-105 for Molecular Imaging of C-Met

Teh,

Amgheib,

et al. 2023

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Induced acetate/acetyl CoA metabolism is highly related to fatty acid synthesis supporting tumor growth [ 98 ] . Therefore, many radiolabeled acetates may be used in glioma imaging, such as 1- 11 C-acetate [ 99 – 100 ] ( 11 C-ACE), 2- 14 C-acetate [ 101 ] ( 14 C-ACE), 2- 18 F-fluoroacetate [ 102 ] ( 18 F-FAC) and 18 F-fluoropivalic acid [ 103 ] ( 18 F-FPIA), a newly designed novel radiotracer based on trimethylacetate.…”

Section: Positron Emission Tomography Tracers For Gliomamentioning

confidence: 99%

Tracers progress for positron emission tomography imaging of glial-related disease

Jia¹,

Xie²

2022

J Biomed Res

View full text Add to dashboard Cite

Glial cells play an essential part in the neuron system. They can not only serve as structural blocks in the human brain but also participate in many biological processes. Extensive studies have shown that astrocytes and microglia play an important role in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, as well as glioma, epilepsy, ischemic stroke, and infections. Positron emission tomography is a functional imaging technique providing molecular-level information before anatomic changes are visible and has been widely used in many above-mentioned diseases. In this review, we focus on the positron emission tomography tracers used in pathologies related to glial cells, such as glioma, Alzheimer's disease, and neuroinflammation.

show abstract

“…CT/PET-CT is time consuming, expensive and low throughput (104). However, alternative fluorescence imaging methods have been developed such as fluorine-18-labelled trimethylacetatebased radiotracer to aid in vivo tumour visualisation (116).…”

Section: Patient Derived Xenografts (Pdx)mentioning

confidence: 99%

Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research

et al. 2022

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is a heterogenous disease associated with variations in presentation, pathology and prognosis. Advanced EOC is typified by frequent relapse and a historical 5-year survival of less than 30% despite improvements in surgical and systemic treatment. The advent of next generation sequencing has led to notable advances in the field of personalised medicine for many cancer types. Success in achieving cure in advanced EOC has however been limited, although significant prolongation of survival has been demonstrated. Development of novel research platforms is therefore necessary to address the rapidly advancing field of early diagnostics and therapeutics, whilst also acknowledging the significant tumour heterogeneity associated with EOC. Within available tumour models, patient-derived organoids (PDO) and explant tumour slices have demonstrated particular promise as novel ex vivo systems to model different cancer types including ovarian cancer. PDOs are organ specific 3D tumour cultures that can accurately represent the histology and genomics of their native tumour, as well as offer the possibility as models for pharmaceutical drug testing platforms, offering timing advantages and potential use as prospective personalised models to guide clinical decision-making. Such applications could maximise the benefit of drug treatments to patients on an individual level whilst minimising use of less effective, yet toxic, therapies. PDOs are likely to play a greater role in both academic research and drug development in the future and have the potential to revolutionise future patient treatment and clinical trial pathways. Similarly, ex vivo tumour slices or explants have also shown recent renewed promise in their ability to provide a fast, specific, platform for drug testing that accurately represents in vivo tumour response. Tumour explants retain tissue architecture, and thus incorporate the majority of tumour microenvironment making them an attractive method to re-capitulate in vivo conditions, again with significant timing and personalisation of treatment advantages for patients. This review will discuss the current treatment landscape and research models for EOC, their development and new advances towards the discovery of novel biomarkers or combinational therapeutic strategies to increase treatment options for women with ovarian cancer.

show abstract

Effective Detection and Monitoring of Glioma Using [18F]FPIA PET Imaging

Cited by 5 publications

References 36 publications

Evaluation of [18F]AlF-EMP-105 for Molecular Imaging of C-Met

Evaluation of [18F]AlF-EMP-105 for Molecular Imaging of C-Met

Tracers progress for positron emission tomography imaging of glial-related disease

Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research

Contact Info

Product

Resources

About